This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morrow, D. A. Articles by de Lemos, J. A. Search for Related Content PubMed PubMed Citation Articles by Morrow, D. A. Articles by de Lemos, J. A. Related Collections Secondary prevention Risk Factors Acute coronary syndromes Other diagnostic testing

(Circulation. 2007;115:949-952.)
© 2007 American Heart Association, Inc.

Editorial

Benchmarks for the Assessment of Novel Cardiovascular Biomarkers

David A. Morrow, MD, MPH; James A. de Lemos, MD

From the TIMI Study Group (D.A.M.), Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass; and the Donald W. Reynolds Cardiovascular Clinical Research Center (J.A.d.L.), University of Texas Southwestern Medical Center, Dallas, Tex.

Correspondence to Dr David A. Morrow, MD, MPH, TIMI Study Group/Cardiovascular Division, Department of Medicine, Brigham & Women’s Hospital, 350 Longwood Ave, 1st Floor, Boston, MA 02115. E-mail dmorrow@partners.org

Key Words: Editorials • angina, unstable • biomarkers • diagnosis • myocardial infarction • prognosis

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
The investigation of novel circulating serum and plasma biomarkers in patients with cardiovascular disease has been accelerating at a remarkable pace. For example, a Medline search that uses the terms "biomarkers" and "acute coronary syndromes" (ACS) reveals an approximate tripling in the number of published reports during the 2-year interval from 2003 to 2004 compared with the period from 2001 to 2002, and this number more than doubled from 2005 to 2006. Although this expanding body of research has established firm evidence for the value of biomarkers, such as for diagnosis and risk assessment among patients with suspected ACS,¹ it has also deluged the clinical and research communities with candidate biomarkers, very few of which are likely to survive the test of time as useful clinical tools.^2,3 It is thus increasingly important for researchers, manufacturers, regulators, and clinicians to critically appraise the value of new biomarkers as they emerge as candidates for further investigation and possible clinical application. The superb report by Wollert and colleagues⁴ in the present issue of Circulation on growth differentiation factor-15 (GDF-15) as a biomarker for prognostic assessment in ACS provides an opportunity to outline a basic set of benchmarks against which new markers can be evaluated.

Article p 962

	Criteria for the Appraisal of Novel Biomarkers

 
Assessment of the clinical potential of a novel biomarker⁵ may be structured around 3 fundamental questions (Figure): (1) Can the clinician measure it? (2) Does it add new information? (3) Does it help the clinician to manage patients?

View larger version (49K):   A, Criteria for assessment of novel . . . [Full Text of this Article]

This article has been cited by other articles:

				T. S. Perlstein and M. A. Creager The Ankle-Brachial Index as a Biomarker of Cardiovascular Risk: It's Not Just About the Legs Circulation, November 24, 2009; 120(21): 2033 - 2035. [Full Text] [PDF]

				M. Helfand, D. I. Buckley, M. Freeman, R. Fu, K. Rogers, C. Fleming, and L. L. Humphrey Emerging Risk Factors for Coronary Heart Disease: A Summary of Systematic Reviews Conducted for the U.S. Preventive Services Task Force Ann Intern Med, October 6, 2009; 151(7): 496 - 507. [Abstract] [Full Text] [PDF]

				A. Rohatgi and J. A. de Lemos The Report Card on Growth Differentiation Factor 15: Consistent Marks But Not Yet Ready for Promotion Circ Cardiovasc Genet, June 1, 2009; 2(3): 209 - 211. [Full Text] [PDF]

				J. Kastrup, J. S. Johansen, P. Winkel, J. F. Hansen, P. Hildebrandt, G. B. Jensen, C. M. Jespersen, E. Kjoller, H. J. Kolmos, I. Lind, et al. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease Eur. Heart J., May 1, 2009; 30(9): 1066 - 1072. [Abstract] [Full Text] [PDF]

				K. S. Woo Perusal of risk stratification of acute myocardial infarction for half a century Eur. Heart J., May 1, 2009; 30(9): 1030 - 1032. [Full Text] [PDF]

				T. S. Perlstein, J. Weuve, M. A. Pfeffer, and J. A. Beckman Red Blood Cell Distribution Width and Mortality Risk in a Community-Based Prospective Cohort Arch Intern Med, March 23, 2009; 169(6): 588 - 594. [Abstract] [Full Text] [PDF]

				A. Gonzalez, B. Lopez, S. Ravassa, J. Beaumont, T. Arias, N. Hermida, A. Zudaire, and J. Diez Biochemical markers of myocardial remodelling in hypertensive heart disease Cardiovasc Res, February 15, 2009; 81(3): 509 - 518. [Abstract] [Full Text] [PDF]

				NACB LMPG Committee Members, G. L. Myers, R. H.M. Christenson, M. Cushman, C. M. Ballantyne, G. R. Cooper, C. M. Pfeiffer, S. M. Grundy, D. R. Labarthe, D. Levy, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging Biomarkers for Primary Prevention of Cardiovascular Disease Clin. Chem., February 1, 2009; 55(2): 378 - 384. [Abstract] [Full Text] [PDF]

				C. W. Hamm, H. Möllmann, J.-P. Bassand, and F. van de Werf CHAPTER 16 Acute Coronary Syndromes ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]

				E. Braunwald Biomarkers in Heart Failure N. Engl. J. Med., May 15, 2008; 358(20): 2148 - 2159. [Full Text] [PDF]

				M. Lankeit, T. Kempf, C. Dellas, M. Cuny, H. Tapken, T. Peter, M. Olschewski, S. Konstantinides, and K. C. Wollert Growth Differentiation Factor-15 for Prognostic Assessment of Patients with Acute Pulmonary Embolism Am. J. Respir. Crit. Care Med., May 1, 2008; 177(9): 1018 - 1025. [Abstract] [Full Text] [PDF]

				M. Nieuwdorp, M. C. Meuwese, H. L. Mooij, C. Ince, L. N. Broekhuizen, J. J. P. Kastelein, E. S. G. Stroes, and H. Vink Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability J Appl Physiol, March 1, 2008; 104(3): 845 - 852. [Abstract] [Full Text] [PDF]

				J. A. de Lemos and M. O'Donoghue The Skinny on Fatty Acid-Binding Protein J. Am. Coll. Cardiol., November 20, 2007; 50(21): 2068 - 2070. [Full Text] [PDF]

				R. P. Giugliano and E. Braunwald The Year in Non ST-Segment Elevation Acute Coronary Syndrome J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1386 - 1395. [Full Text] [PDF]